(S1 (S (NP (NP (NN AVE8062)) (: :) (NP (NP (DT a) (JJ new) (NN combretastatin) (NN derivative) (JJ vascular)) (VP (VBG disrupting) (NP (NN agent)))) (. .))))
(S1 (S (S (S (NP (NN Angiogenesis)) (VP (VBZ has) (NP (DT an) (JJ essential) (NN role)) (PP (IN in) (S (VP (VP (VBG promoting)) (CC and) (VP (VBG supporting) (NP (NN tumor) (NN growth)))))))) (CC and) (S (NP (PRP it)) (VP (VBZ is) (NP (DT an) (JJ important) (JJ therapeutic) (NN target))))) (. .)))
(S1 (S (S (NP (DT The) (NN tumor) (JJ vascular) (NN network)) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (PP (IN of) (NP (ADJP (ADJP (JJ pro-angiogenic)) (CC and) (ADJP (JJ inhibitory))) (NNS factors))) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (JJ endothelial) (NNS cells)) (CC and) (NP (JJ extracellular) (NN matrix)))))))))) (. .)))
(S1 (S (S (NP (JJ Different) (JJ antiangiogenic) (NNS therapeutics)) (VP (VBP have) (VP (VBN been) (VP (VBN developed) (S (VP (TO to) (VP (VB improve) (NP (NN tumor) (NN control)) (PP (IN through) (NP (NP (JJ vascular-targeting) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NN VTA)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NN VTAs)) (VP (MD can) (VP (VB be) (VP (VBN divided) (PP (IN into) (NP (NP (CD two) (NNS groups)) (: :) (NP (NP (NP (JJ antiangiogenic) (NNS agents)) (CC and) (NP (JJ vascular-disrupting) (NNS agents))) (PRN (-LRB- -LRB-) (NP (NNS VDAs)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NNS VTAs)) (VP (VBP inhibit) (NP (NP (JJ specific) (NNS factors)) (VP (VBN required) (S (VP (VP (TO to) (VP (VB induce))) (CC and) (VP (VBP direct) (NP (DT the) (JJ angiogenic) (NN process))))))) (, ,) (PP (PP (IN with) (NP (NP (JJ major) (NN activity)) (PP (IN against) (NP (JJ small) (NN tumor) (NNS masses))))) (CC and) (PP (IN at) (NP (DT the) (NN tumor) (NN periphery)))) (, ,) (S (VP (VBG encompassing) (NP (NP (JJ monoclonal) (NNS antibodies)) (CC and) (NP (JJ small) (NNS molecules)) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (DT the) (NN tyrosine) (NN kinase) (NN domain)) (PP (IN of) (NP (DT the) (NN VEGF) (NN receptor))))))))))) (. .)))
(S1 (S (NP (NNS VDAs)) (ADVP (RB specifically)) (VP (VP (VBP target)) (CC and) (VP (VBP destroy) (NP (NP (JJ well-established) (NN tumor) (NNS vessels)) (PP (IN with) (NP (NP (NP (NN ischemia)) (CC and) (NP (NN destruction))) (PP (IN of) (NP (NP (JJ large) (NNS masses)) (PP (IN with) (NP (NP (NP (JJ central) (JJ hemorrhagic) (NN necrosis)) (CC and) (NP (NN survival))) (PP (IN of) (NP (DT a) (JJ thin) (JJ peripheral) (NN tumor) (NN layer)))))))))))) (. .)))
(S1 (S (S (NP (NN VDAs)) (VP (MD can) (VP (VB be) (VP (VBN divided) (PP (IN into) (NP (NP (NNS biologics)) (, ,) (PP (JJ such) (IN as) (NP (ADJP (ADJP (JJ ligand-based)) (, ,) (CC and) (ADJP (JJ small-molecule))) (NNS agents))))))))) (: ;) (S (NP (DT this) (JJ second) (NN group)) (VP (VBZ includes) (NP (NP (JJ small-molecule) (NNS VDAs)) (PP (IN like) (NP (NP (NNS flavonoids)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ 5,6-dimethylxanthenone-4-acetic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN DMXAA)) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ microtubule-destabilizing) (NNS agents))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT this) (NN review))) (NP (PRP we)) (VP (MD will) (VP (VB discuss) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NP (NN action)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (ADJP (ADJP (JJ preclinical)) (CC and) (ADJP (JJ clinical))) (NNS results)) (, ,)) (PP (IN of) (NP (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJS most) (JJ promising) (NN antitubulin) (NNS agents)))) (: :) (NP (NP (DT the) (JJ combretastatin) (NN A4-phosphate) (NN derivative)) (, ,) (NP (NN AVE8062A)))))))))) (. .)))
